Cleared Traditional

K221257 - SpectraWAVE Imaging System (FDA 510(k) Clearance)

Feb 2023
Decision
302d
Days
Class 2
Risk

K221257 is an FDA 510(k) clearance for the SpectraWAVE Imaging System. This device is classified as a System, Imaging, Optical Coherence Tomography (oct) (Class II - Special Controls, product code NQQ).

Submitted by Spectrawave, Inc. (Bedford, US). The FDA issued a Cleared decision on February 28, 2023, 302 days after receiving the submission on May 2, 2022.

This device falls under the Cardiovascular FDA review panel. Regulated under 21 CFR 892.1560. This Device Uses Back-reflected Light To Create Two-dimensional Images Versus Back-reflected Sound Waves As Are Used In Ultrasound Imaging..

Submission Details

510(k) Number K221257 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 02, 2022
Decision Date February 28, 2023
Days to Decision 302 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF

Device Classification

Product Code NQQ - System, Imaging, Optical Coherence Tomography (oct)
Device Class Class II - Special Controls
CFR Regulation 21 CFR 892.1560
Definition This Device Uses Back-reflected Light To Create Two-dimensional Images Versus Back-reflected Sound Waves As Are Used In Ultrasound Imaging.